time to review and launch a clinical trial, standardizing agreements with industry, developing a core facility to support imaging and radiation therapy trials, and strategic planning and trial prioritization at the national level. He seemed proudest of NCI's new uniform clinical trial datamanagement system, which operates across more than 3,000 trial sites. "There is no country, there is no pharmaceutical organization that has a way to enroll patients 24/7 like we have," said Doroshow.
In a phone interview, Sheila Prindiville, M.D., M.P.H., director of NCI's Coordinating Center for Clinical Trials, pointed to NCI's June 2012 release of six Requests for Applications for the new clinical trial system as "a major accomplishment" in setting national clinical trial priorities. The applications will be reviewed this year, with funding awards issued in March 2014.
Two ongoing changes that should increase efficiency and help with clinical trial accrual are a streamlined patient consent form and a centralized institutional review board (IRB). In December 2012, the Association for the Accreditation of Human Research Protection Programs awarded NCI's centralized IRB full accreditation, and it is now the NCI's IRB of record. "We believe this will simplify things for centers to participate and remove what may have been a barrier," said Prindiville.
Several working groups had tackled revising patient informed-consent forms. "Over time, we found the lengths of informed-consent forms had grown-some even to 35 pages-and seemed like a legal document," explained Prindiville. "A goal of the IOM was to update NCI's consent document to be different for each trial but with a standard template, kept to a bare minimum in length while transmitting the central information of risks and benefits to patients," she said. "We hope the streamlined conveyance will help with accrual for clinical trials by making it less burdensome for physicians and patients."
Many of the changes have been well received. "I think the thing the NCI has done well is generate a list of things they want to do, and through James Doroshow and Sheila Prindiville's leadership, they have done it," said James To strengthen the cooperative groups and streamline operations, NCI downsized the nine adult cooperative groups and one pediatric to four adult groups and the Children's Oncology Group. "Is this iteration the best Historically, ACRIN had the best radiologic science researchers and programs in the country. ECOG is one of the longest-standing and largest clinical trials organizations in the NCI system, perhaps in the world." Although both groups had been successful, they had no overlap in expertise.
To best organize its research capabilities, the new group has established three scientific programs: a strong laboratorybased and imaging-based Biomarker Sciences Program; the Therapeutic Studies Program, which addresses 11 tumor types; and a large Cancer Control and Outcomes Program, addressing prevention, diagnosis, early detection, patient-centered outcomes, survivorship, and comparative-and costeffectiveness research.
"From the very beginning, we saw a tremendous synergy between the scientific programs of both groups. It was clear to us that we could strengthen each other if we were to become one organization." Comis said that the merger has brought enthusiasm and enrichment to their research. ECOG-ACRIN is putting together "a virtual data warehouse for images, pathology, clinical research, and clinical data that, when finished, will be available to everybody. This wouldn't have happened with ECOG on its own or ACRIN on its own, said Comis. He finds the scientific possibilities with the new group "very exciting. It is something that has allowed us to jump to the cutting edge."
